Event-Driven Stocks

Indivior Pharmaceuticals, Inc.

INDVNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 3 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22
Revenue$1.24B$1.19B$1.09B$901.0M
Operating income$262.0M$75.0M−$152.0M−$81.0M
Net income$210.0M$61.0M−$126.0M−$44.0M
Total assets$1.20B$1.32B$1.76B—
Total liabilities$1.30B$1.65B$1.94B—
Equity−$98.0M−$337.0M−$184.0M−$15.0M
EPS (diluted)$1.64$0.05$-0.92$-0.32
Shares out.124.7M133.0M137.0M139.0M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
21.1%
Net margin
16.9%
Return on equity
−214.3%
Return on assets
17.5%
Return on capital (ROCE)
91.3%
Liabilities / assets
108.2%
Debt / equity
—
Book value / share
$-0.79
Revenue growth (YoY)
4.3%
Net income growth (YoY)
244.3%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-0.70distress
Accruals / assets
19.7%high accruals
Beneish M-Score
-1.88normal
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
49
/ 100
Profitability 80Growth 100Catalyst 67Earnings quality 0Financial strength 0

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 3 warning● 2 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Operating margin is positive
  • Revenue is growing year-over-year

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • OPVEEMay 22, 2023
  • PERSERIS KITJul 27, 2018
  • SUBLOCADENov 30, 2017
  • SUBUTEXOct 8, 2002
  • SUBOXONEOct 8, 2002
  • BUPRENEXDec 29, 1981

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202613.7M5.3+7.1%
Apr 30, 202612.8M6.8-7.9%
Apr 15, 202613.9M9.1+4.0%
Mar 31, 202613.4M4.0+9.8%
Mar 13, 202612.2M3.0+21.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)